Imjudo, Tremelimumab astrazeneca(tremelimumab)
Imjudo (tremelimumab) is an antibody pharmaceutical. Tremelimumab was first approved as Imjudo on 2022-10-21. It is used to treat hepatocellular carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma and non-small-cell lung carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Imjudo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tremelimumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Imjudo | tremelimumab-actl | AstraZeneca | N-761289 RX | 2022-10-21 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imjudo | Biologic Licensing Application | 2022-10-21 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
tremelimumab, Imjudo, AstraZeneca AB | |||
| 2029-10-21 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
918 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 65 | 65 | 3 | — | 1 | 101 | |
| Non-small-cell lung carcinoma | D002289 | 37 | 55 | 16 | — | — | 91 | ||
| Prostatic neoplasms | D011471 | C61 | 17 | 29 | 2 | — | — | 43 | |
| Colorectal neoplasms | D015179 | 20 | 26 | 2 | — | — | 40 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 18 | 20 | 1 | — | — | 32 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 12 | 21 | 5 | — | — | 32 |
| Small cell lung carcinoma | D055752 | 10 | 10 | 3 | — | — | 20 | ||
| Urinary bladder neoplasms | D001749 | C67 | 6 | 14 | 1 | — | — | 17 | |
| Sarcoma | D012509 | 8 | 12 | 1 | — | — | 17 | ||
| Glioblastoma | D005909 | EFO_0000515 | 7 | 7 | 2 | — | 1 | 16 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 21 | 18 | — | — | — | 34 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 17 | 17 | — | — | 2 | 32 |
| Uveal neoplasms | D014604 | EFO_1001230 | 13 | 15 | — | — | — | 24 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 12 | 13 | — | — | — | 19 |
| Urologic neoplasms | D014571 | C64-C68 | 11 | 8 | — | — | — | 14 | |
| Adenocarcinoma | D000230 | 2 | 11 | — | — | — | 13 | ||
| Uterine cervical neoplasms | D002583 | 8 | 6 | — | — | 1 | 13 | ||
| Myelodysplastic syndromes | D009190 | D46 | 10 | 2 | — | — | — | 12 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 9 | 7 | — | — | — | 12 | |
| Myeloid leukemia acute | D015470 | C92.0 | 10 | 1 | — | — | — | 11 |
Show 136 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 4 | — | — | — | — | 4 | |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | C92.2 | 3 | — | — | — | — | 3 | |
| Primary myelofibrosis | D055728 | D47.4 | 2 | — | — | — | — | 2 | |
| Ovarian epithelial carcinoma | D000077216 | 2 | — | — | — | — | 2 | ||
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
| Myeloid leukemia chronic-phase | D015466 | 1 | — | — | — | — | 1 | ||
| Thrombocytosis | D013922 | D75.83 | 1 | — | — | — | — | 1 | |
| Small cell carcinoma | D018288 | 1 | — | — | — | — | 1 | ||
| Female genital neoplasms | D005833 | 1 | — | — | — | — | 1 | ||
| Hydronephrosis | D006869 | EFO_0005562 | N13.30 | 1 | — | — | — | — | 1 |
Show 16 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TREMELIMUMAB |
| INN | tremelimumab |
| Description | Tremelimumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5GGV:H|heavy chain
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLY
LQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH
>5GGV:L|light chain
DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 5GGU, 5GGV |
| CAS-ID | 745013-59-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108658 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11771 |
| UNII ID | QEN1X95CIX (ChemIDplus, GSRS) |
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,508 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,425 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more